Form 4: Liquidia CFO/COO Sells Shares for Tax Obligations
Insider Transaction Report
Liquidia Corp's CFO and COO, Michael Kaseta, reported the acquisition of common stock from PSU conversion and subsequent sale of shares to cover tax liabilities.
Summary
- Michael Kaseta, CFO and COO of Liquidia Corp (LQDA), reported changes in his beneficial ownership of company common stock.
- On October 10, 2025, 5,828 Performance Stock Units (PSUs) converted into common stock on a one-for-one basis.
- Following the PSU conversion, beneficial ownership stood at 364,276 shares of common stock.
- On October 13, 2025, Mr. Kaseta sold 11,630 shares of common stock at a price of $23.41 per share.
- The sale was executed pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
- The purpose of the sale was to cover taxes associated with the settlement of Restricted Stock Units (RSUs) and PSUs granted on January 11, 2023, January 11, 2024, and January 15, 2024.
- After the sale, Mr. Kaseta's direct beneficial ownership of common stock was 352,646 shares.
- The reported beneficial ownership includes 38,958 unvested RSUs from a January 11, 2023 grant, 52,453 unvested RSUs and 28,125 unvested RSUs from January 11, 2024 and January 15, 2024 grants respectively, 112,797 unvested RSUs from a January 11, 2025 grant, and 11,257 shares acquired under the Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it is a planned transaction for tax purposes, which is a routine event and not indicative of a negative outlook on the company. The vesting of equity awards is a positive for management alignment.
Positives
- The vesting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) indicates ongoing equity compensation for management, aligning their interests with shareholders.
- The sale of shares was pre-planned under a Rule 10b5-1 plan, reducing concerns about opportunistic insider selling.
Negatives
- The sale of 11,630 shares by a key executive, even for tax purposes, results in a reduction of their direct ownership stake in the company.
Future Outlook
The filing details future vesting schedules for various equity grants, including 25% of 93,250 PSUs vesting on January 11, 2025, with the remainder vesting ratably quarterly over three years thereafter. No other forward-looking statements or guidance are provided.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices involving equity grants and tax-related sales.
Comparison to Industry Standards
- The use of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) as part of executive compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with company performance and long-term shareholder value.
- The adoption of a Rule 10b5-1 plan for stock sales is a standard corporate governance practice for insiders, providing an affirmative defense against insider trading allegations by pre-scheduling transactions.
Stakeholder Impact
- Shareholders: The transaction is a routine insider disclosure and is unlikely to have a significant direct impact on shareholders, as it reflects standard executive compensation and tax planning.
- Employees: The details of equity grants and vesting schedules may be relevant to employees participating in similar compensation plans.
Next Steps
- Continued vesting of the remaining 93,250 PSUs granted on January 11, 2024, on a quarterly basis over three years after January 11, 2025.
- Continued vesting of various Restricted Stock Units (RSUs) granted on January 11, 2023, January 11, 2024, January 15, 2024, and January 11, 2025, according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 01/11/2023 | Date of grant for 124,667 Restricted Stock Units (RSUs) to the Reporting Person. |
| 12/15/2023 | Date the Reporting Person adopted a Rule 10b5-1 plan for future transactions. |
| 01/11/2024 | Date of grant for 93,250 Performance Stock Units (PSUs) and 93,250 Restricted Stock Units (RSUs) to the Reporting Person. |
| 01/15/2024 | Date of grant for 50,000 Restricted Stock Units (RSUs) to the Reporting Person. |
| 01/11/2025 | Date of grant for 112,797 Restricted Stock Units (RSUs) to the Reporting Person; also the vesting date for 25% of the 93,250 PSUs granted on January 11, 2024. |
| 10/10/2025 | Transaction date for the conversion of 5,828 Performance Stock Units (PSUs) into common stock. |
| 10/13/2025 | Transaction date for the sale of 11,630 shares of common stock. |
| 10/15/2025 | Date the Form 4 was signed. |
Keywords
Liquidia Corp, LQDA, SEC Form 4, Insider Trading, Stock Sale, Performance Stock Units, Restricted Stock Units, Rule 10b5-1 Plan, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.